Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial

Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression

(2020) Daniel Rathkey et al.   Journal of Thoracic Oncology

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

(2019) Arnaud Scherpereel et al.   LANCET ONCOLOGY

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial

(2019) Maria J Disselhorst et al.   Lancet Respiratory Medicine

Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma

(2019) Marc Ladanyi et al.   Genome Medicine

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer

(2019) Constantia Pantelidou et al.   Cancer Discovery

Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas

(2019) Robin Guo et al.   Journal of Thoracic Oncology

PD-1 blockade with nivolumab in patients with recurrent Malignant Pleural Mesothelioma

(2018) Josine Quispel-Janssen et al.   Journal of Thoracic Oncology

Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma

(2018) Vasiliki Panou et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of PARP and Immune-Checkpoint Inhibitor Combinations

(2018) Ross A Stewart et al.   CANCER RESEARCH

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness

(2018) Jianfeng Shen et al.   CANCER RESEARCH

Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes

(2018) Marta Betti et al.   GENES CHROMOSOMES & CANCER

Integrative Molecular Characterization of Malignant Pleural Mesothelioma

(2018) Julija Hmeljak et al.   Cancer Discovery

A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair

(2017) Rossella Parrotta et al.   Journal of Thoracic Oncology

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Robert L Coleman et al.   LANCET

BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation

(2017) Angela Bononi et al.   NATURE

Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells

(2015) Shuhei Hakiri et al.   CANCER SCIENCE

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial

(2015) Lee M Krug et al.   LANCET ONCOLOGY

Germline Mutations in BAP1 Impair Its Function in DNA Double-Strand Break Repair

(2014) I. H. Ismail et al.   CANCER RESEARCH

PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1

(2013) Giulia Pinton et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair

(2013) H. Yu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma

(2011) Sara Busacca et al.   JOURNAL OF PATHOLOGY